IR-Med Croissance future

Future contrôle des critères 2/6

IR-Med is forecast to grow earnings and revenue by 78.7% and 192.4% per annum respectively while EPS is expected to grow by 77.4% per annum.

Informations clés

78.7%

Taux de croissance des bénéfices

77.4%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.4%
Taux de croissance des recettes	192.4%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	20 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

OTCPK:IRME - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	6	-1	N/A	N/A	1
12/31/2024	1	-3	N/A	N/A	1
6/30/2024	N/A	-3	-2	-2	N/A
3/31/2024	N/A	-4	-3	-3	N/A
12/31/2023	N/A	-5	-3	-3	N/A
9/30/2023	N/A	-6	-3	-3	N/A
6/30/2023	N/A	-5	-3	-3	N/A
3/31/2023	N/A	-5	-4	-4	N/A
12/31/2022	N/A	-5	-3	-3	N/A
9/30/2022	N/A	-4	-3	-3	N/A
6/30/2022	N/A	-4	-3	-3	N/A
3/31/2022	N/A	-4	-3	-3	N/A
12/31/2021	N/A	-4	-3	-2	N/A
9/30/2021	N/A	-3	-2	-2	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-1	-1	-1	N/A
12/31/2020	N/A	-1	0	0	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: IRME is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: IRME is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: IRME is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: IRME's revenue (192.4% per year) is forecast to grow faster than the US market (8.9% per year).

Croissance élevée des revenus: IRME's revenue (192.4% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if IRME's Return on Equity is forecast to be high in 3 years time

IR-Med Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

IR-Med Inc. Announces Chief Executive Officer Changes

IR-Med Inc. Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers

IR-Med Inc. has filed an IPO in the amount of $8 million.

IR-Med Inc. Appoints Avital Rosenberg as A Class I Director and Member of the Audit Committee

IR-Med Inc.’s PressureSafe Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Hmo

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

IR-Med Inc., Annual General Meeting, Nov 07, 2023

IR-MED Announces Executive Changes Effective as of October 15, 2023

Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024

IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board

Ir-Med Inc. Announces Interim Results from A Clinical Study of Pressuresafe

IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board

IR-Med Inc., Annual General Meeting, Dec 12, 2022

IR-Med Announces Appointment of Moshe Gerber as Chief Executive Officer

International Display Advertising, Inc. (OTCPK:IDAD.D) completed the acquisition of IR Med, Ltd.

International Display Advertising, Inc. announced that it expects to receive $5 million in funding

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance